CL|Analyst Targets
CL|Company Info
CL|Insider Trading
CL|Fundamentals
CL|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $0.99 | - | - |
| Q3'26 | $0.95 | $0.97 | +1.7% |
| Q2'26 | $0.95 | $0.99 | +4.5% |
| Q1'26 | $0.96 | $0.97 | +1.4% |
| Q4'25 | $0.94 | $0.95 | +1.1% |
| Q3'25 | $0.89 | $0.91 | +2.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $5.5B | - | - |
| Q3'26 | $5.5B | $5.4B | -2.3% |
| Q2'26 | $5.5B | $5.4B | -2.9% |
| Q1'26 | $5.3B | $5.3B | -0.2% |
| Q4'25 | $5.3B | $5.2B | -0.8% |
| Q3'25 | - | $5.1B | - |
CL|Monthly Returns
Market Data
CL Stock Snapshot
- Market cap
- 78.51B
- P/E ratio
- 38.2
- Day range
- $95.30 – $98.00
- News sentiment
- 55/100 · Neutral
- Analyst target
- $101.70 (+4.9%)
- Consensus
- Buy · 32 analysts
CL is in a holding pattern - neither trend nor momentum has taken control. Earnings and guidance carry more weight than macro data at this capitalisation.
Reverse DCF
What growth is priced into CL?
At today's price, Colgate-Palmolive Company needs to grow free cash flow about -0.6% a year for 3 years, slowing to a long-run rate by year 10, to justify its valuation at a 6.00% cost of capital. Over the last five years its revenue has trended at 4.3% a year, so the market is asking for 4.9 percentage points below its own delivered rate. On that basis CL looks priced below what its own growth record supports.
- Implied FCF growth
- -0.6%
- Growth trend
- 4.3%
- Growth gap
- -4.9 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 6.00%
- Beta
- 0.34
Behaviour On Record
What CL's own history says about today's numbers
- Realized volatility (21d)
- 27.6% 94th pct
- Below its peak
- -8.8%
- vs 200-day average
- +10.4%
- Up days (1y)
- 53%
Colgate-Palmolive Company is currently running 27.6% annualised volatility over the last 21 sessions. Measured against CL's own 13 years of daily returns rather than a market-wide average, that is the 94th percentile — an extreme by its own standards, against a typical reading of 15.9%.
CL is trading -8.8% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -16.0%, and the deepest was -25.3% in 2018. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +10.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 92nd percentile — a wider gap than this stock usually carries. Over the past year CL closed higher on 53% of sessions, and it is currently 2 sessions into a rising streak.
On November specifically: over 13 years of records, CL finished the month higher 10 of 13 times, with a median return of +3.2% and an average of +2.3%. Its strongest month historically has been November at +2.3% on average, its weakest September at -2.0%.
Overnight risk is measurable too: CL has opened more than 2% away from the prior close in 27 of 3,268 sessions (0.8% of the time), with the largest gaps running +4.7% and -6.4%.
Across the last 4 dated reports on file, CL moved an average of 1.9% in the session after earnings, closing higher 2 of those 4 times, with a median move of +0.5% and a largest of +2.9%.
All figures computed from 3,269 daily closes between 2013-11-06 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against CL's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of CL's sector?
Colgate-Palmolive Company sits in the Consumer Staples sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
Analyst Consensus Estimates
What do analysts expect CL to earn?
Analysts expect Colgate-Palmolive Company to earn $3.92 per share in the fiscal year ending Dec 2026 and $4.60 in the fiscal year ending Dec 2029, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.
Analyst Rating Changes
Are analysts turning bullish or bearish on CL?
Barclays most recently reiterated its rating on Colgate-Palmolive Company to Equal-Weight on Nov 3, 2026 with a price target of $95 (from $87). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Barclays: Equal-Weight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Earnings Release, Scored
What did Colgate-Palmolive Company's latest earnings release say?
Most important lines
- 1
We are recognized for our leadership and innovation in promoting community wellbeing and improving children’s oral health through our Colgate Bright Smiles, Bright Futures program, which has reached approximately two billion children and their families since 1991.
New this quarter - 2
“We remain focused on executing our 2030 strategy, with an emphasis on driving premium, science-based innovation, and we continue to invest behind our brands globally supported by another double-digit increase in advertising this quarter.
New this quarter - 3
The Company now expects organic sales growth to be broadly in line with its nine-month performance (versus 1% to 4% previously).
New this quarter
Peers & ETF holders
CL peers & ETF holders
Household & Personal ProductsMarket cap · today
News & sentiment
What is the news saying about CL?
CL rose 11.1% over the month to Nov 6. News tone held between 19 and 87 from Oct 6 to Oct 8, then dropped to 24 on Oct 9.
- Oct 14 +3.4%same day: Is Colgate-Palmolive (CL) Still A Bargain On Cash Flow?
- Oct 23 -3.6%same day: Colgate-Palmolive (CL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Nov 4 +3.3%same day: Colgate-Palmolive: Improving Execution And A Valuation Discount Make It A Buy
Technical analysis
How strong is CL's momentum right now?
On the daily chart CL ranks at the 57th percentile for momentum against 1,060 stocks and ETFs, a neutral reading.
Institutional ownership
Are big funds buying or selling CL?
90 of the 222 tracked managers added to CL in their latest 13F and 126 trimmed. Together they own 66.8% of the company, worth $49.2B. BlackRock and Vanguard Capital Management alone hold 15.1%.
- 1BlackRock, Inc.8.64%$6.4B positionTrimmed 3.8% last quarter
- $4.8B positionAdded 0.1% last quarter
- 3State Street Corp5.81%$4.3B positionTrimmed 1.5% last quarter
- $2.2B positionAdded 0.8% last quarter
- $2.1B positionAdded 1.1% last quarter
- 6Morgan Stanley2.73%$2.0B positionAdded 5.7% last quarter
- $1.1B positionTrimmed 1.6% last quarter
- 8Deutsche Bank AG1.45%$1.1B positionTrimmed 1.5% last quarter
- 9Norges Bank1.20%$888.0M positionTrimmed 11.2% last quarter
- 10FMR LLC (Fidelity)1.11%$823.6M positionTrimmed 0.3% last quarter
Congressional trading
Is Congress trading CL?
8 members of Congress disclosed 18 CL trades between Apr 5, 2018 and Sep 2, 2026: 5 buys and 13 sells, about $144.0K in estimated value.
What stands out
Click one to highlight its trades in the chartDiscover more
How has CL done against its peers?
Over the six months to Nov 6, CL returned +10.0%. Of the 14 related stocks and ETFs, 7 did better, led by EL at +27.7%.
- 1ELThe Estée Lauder Companies Inc.up 27.7%+17.7 pts
- 2TGTTarget Corporationup 22.1%+12.2 pts
- 3KOThe Coca-Cola Companyup 21.3%+11.3 pts
- 4MNSTMonster Beverage Corporationup 20.1%+10.1 pts
- 5PMPhilip Morris International Inc.up 17.2%+7.2 pts
- 6CHDChurch & Dwight Co., Inc.up 15.5%+5.6 pts
- 7PGThe Procter & Gamble Companyup 12.3%+2.3 pts
- 8CLThis stockup 10.0%
- 15PEPPepsiCo, Inc.down 9.2%−19.2 pts